162 related articles for article (PubMed ID: 24024947)
1. Candidate molecules for chemical chaperone therapy of GM1-gangliosidosis.
Higaki K; Ninomiya H; Suzuki Y; Nanba E
Future Med Chem; 2013 Sep; 5(13):1551-8. PubMed ID: 24024947
[TBL] [Abstract][Full Text] [Related]
2. DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts.
Fantur K; Hofer D; Schitter G; Steiner AJ; Pabst BM; Wrodnigg TM; Stütz AE; Paschke E
Mol Genet Metab; 2010 Jul; 100(3):262-8. PubMed ID: 20409738
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of pharmacological chaperoning for human β-galactosidase.
Suzuki H; Ohto U; Higaki K; Mena-Barragán T; Aguilar-Moncayo M; Ortiz Mellet C; Nanba E; Garcia Fernandez JM; Suzuki Y; Shimizu T
J Biol Chem; 2014 May; 289(21):14560-8. PubMed ID: 24737316
[TBL] [Abstract][Full Text] [Related]
4. The pharmacological chaperone N-n-butyl-deoxygalactonojirimycin enhances β-galactosidase processing and activity in fibroblasts of a patient with infantile GM1-gangliosidosis.
Mohamed FE; Al Sorkhy M; Ghattas MA; Al-Gazali L; Al-Dirbashi O; Al-Jasmi F; Ali BR
Hum Genet; 2020 May; 139(5):657-673. PubMed ID: 32219518
[TBL] [Abstract][Full Text] [Related]
5. The potential action of galactose as a "chemical chaperone": increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient.
Caciotti A; Donati MA; d'Azzo A; Salvioli R; Guerrini R; Zammarchi E; Morrone A
Eur J Paediatr Neurol; 2009 Mar; 13(2):160-4. PubMed ID: 18571950
[TBL] [Abstract][Full Text] [Related]
6. Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in β-galactosidase deficiency.
Higaki K; Li L; Bahrudin U; Okuzawa S; Takamuram A; Yamamoto K; Adachi K; Paraguison RC; Takai T; Ikehata H; Tominaga L; Hisatome I; Iida M; Ogawa S; Matsuda J; Ninomiya H; Sakakibara Y; Ohno K; Suzuki Y; Nanba E
Hum Mutat; 2011 Jul; 32(7):843-52. PubMed ID: 21520340
[TBL] [Abstract][Full Text] [Related]
7. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
Suzuki Y
Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
[TBL] [Abstract][Full Text] [Related]
8. A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.
Takai T; Higaki K; Aguilar-Moncayo M; Mena-Barragán T; Hirano Y; Yura K; Yu L; Ninomiya H; García-Moreno MI; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
Mol Ther; 2013 Mar; 21(3):526-32. PubMed ID: 23337983
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy.
Rigat BA; Tropak MB; Buttner J; Crushell E; Benedict D; Callahan JW; Martin DR; Mahuran DJ
Mol Genet Metab; 2012 Sep; 107(1-2):203-12. PubMed ID: 22784478
[TBL] [Abstract][Full Text] [Related]
10. A new type of pharmacological chaperone for G
Schalli M; Weber P; Tysoe C; Pabst BM; Thonhofer M; Paschke E; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
Bioorg Med Chem Lett; 2017 Aug; 27(15):3431-3435. PubMed ID: 28600215
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of human β-galactosidase: structural basis of Gm1 gangliosidosis and morquio B diseases.
Ohto U; Usui K; Ochi T; Yuki K; Satow Y; Shimizu T
J Biol Chem; 2012 Jan; 287(3):1801-12. PubMed ID: 22128166
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast screening for chaperone therapy in beta-galactosidosis.
Iwasaki H; Watanabe H; Iida M; Ogawa S; Tabe M; Higaki K; Nanba E; Suzuki Y
Brain Dev; 2006 Sep; 28(8):482-6. PubMed ID: 16617000
[TBL] [Abstract][Full Text] [Related]
13. Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB₁ alleles causing GM1-gangliosidosis and Morquio B disease.
Fantur KM; Wrodnigg TM; Stütz AE; Pabst BM; Paschke E
J Inherit Metab Dis; 2012 May; 35(3):495-503. PubMed ID: 22033734
[TBL] [Abstract][Full Text] [Related]
14. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis.
Aguilar-Moncayo M; Takai T; Higaki K; Mena-Barragán T; Hirano Y; Yura K; Li L; Yu Y; Ninomiya H; García-Moreno MI; Ishii S; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
Chem Commun (Camb); 2012 Jul; 48(52):6514-6. PubMed ID: 22618082
[TBL] [Abstract][Full Text] [Related]
15. Chemical chaperone therapy for GM1-gangliosidosis.
Suzuki Y
Cell Mol Life Sci; 2008 Feb; 65(3):351-3. PubMed ID: 18202827
[TBL] [Abstract][Full Text] [Related]
16. N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
Kasperzyk JL; El-Abbadi MM; Hauser EC; D'Azzo A; Platt FM; Seyfried TN
J Neurochem; 2004 May; 89(3):645-53. PubMed ID: 15086521
[TBL] [Abstract][Full Text] [Related]
17. Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosis.
Zhang S; Bagshaw R; Hilson W; Oho Y; Hinek A; Clarke JT; Callahan JW
Biochem J; 2000 Jun; 348 Pt 3(Pt 3):621-32. PubMed ID: 10839995
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders.
Kwak JE; Son MY; Son YS; Son MJ; Cho YS
Biochem Biophys Res Commun; 2015 Feb; 457(4):554-60. PubMed ID: 25600812
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of C-5a-substituted derivatives of 4-epi-isofagomine: notable β-galactosidase inhibitors and activity promotors of GM1-gangliosidosis related human lysosomal β-galactosidase mutant R201C.
Thonhofer M; Weber P; Gonzalez Santana A; Tysoe C; Fischer R; Pabst BM; Paschke E; Schalli M; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
Carbohydr Res; 2016 Jun; 429():71-80. PubMed ID: 27063389
[TBL] [Abstract][Full Text] [Related]
20. Lysosomal accumulation of Trk protein in brain of GM₁ -gangliosidosis mouse and its restoration by chemical chaperone.
Takamura A; Higaki K; Ninomiya H; Takai T; Matsuda J; Iida M; Ohno K; Suzuki Y; Nanba E
J Neurochem; 2011 Aug; 118(3):399-406. PubMed ID: 21574998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
